Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice

2 May 2011

Abstract excerpt

Pharmacologic induction of fetal hemoglobin (HbF) expression is an effective treatment strategy for sickle cell disease (SCD) and β-thalassemia. Pomalidomide is a potent structural analog of thalidomide and member of a new class of immunomodulatory drugs. Recent reports demonstrated that pomalidomide reduced or eliminated transfusion requirements in certain hematologic malignancies and induced HbF ex vivo in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood groups and transfusion
Share to Epigenetics and DNA Methylation
Share to Hemoglobinopathies and Related Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21536862
DOI: 10.1182/blood-2010-11-319137

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell micePMID 21536862Read ↗

Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitorsSemantic proximity Read ↗

Pharmacological Induction of Fetal Hemoglobin in β-Thalassemia and Sickle Cell Disease: An Updated PerspectiveSemantic proximity Read ↗

Development of pathophysiologically relevant models of sickle cell disease and β-thalassemia for therapeutic studies.Semantic proximity Read ↗

Development of a double shmiR lentivirus effectively targeting both BCL11A and ZNF410 for enhanced induction of fetal hemoglobin to treat β-hemoglobinopathiesSemantic proximity Read ↗

Identification of small molecule agonists of fetal hemoglobin expression for the treatment of sickle cell diseaseSemantic proximity Read ↗

Forced chromatin looping raises fetal hemoglobin in adult sickle cells to higher levels than pharmacologic inducersSemantic proximity Read ↗

Pharmacologic induction of <scp>PGC</scp>‐1α stimulates fetal haemoglobin gene expressionSemantic proximity Read ↗

Understanding mechanisms of gamma-globin gene regulation to develop strategies for pharmacological fetal hemoglobin induction.Semantic proximity Read ↗

Inactivation of HDAC 1 or HDAC 2 induces gamma globin expression without altering cell cycle or proliferationSemantic proximity Read ↗

Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse modelSemantic proximity Read ↗

A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correctionSemantic proximity Read ↗

Pharmacological Induction of FOXO3 Is a Potential Treatment for Sickle Cell DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.